Clinical trial
A Trial of Placebo Versus Enzastaurin for Lung Cancer Prevention in Former…
NCT00414960 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00414960 |
|---|---|
| Title | A Trial of Placebo Versus Enzastaurin for Lung Cancer Prevention in Former Smokers |
| Official title | Phase IIB Randomized, Placebo-Controlled, Double-Blind Study of Enzastaurin HCL (LY317615) for Lung Cancer Prevention in Former Smokers |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | Enzastaurin, Placebo |
| Enrollment | 40 |
| Start date | Dec 1, 2007 |
| Primary completion | Sep 1, 2010 |
| Completion | Sep 1, 2010 |
| First posted | Dec 22, 2006 |
| Last update posted | Sep 21, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: